摘要
目的观察并评价托特罗定治疗Ⅲ型前列腺炎疗效和安全性。方法将80例Ⅲ型慢性前列腺炎的门诊患者随机分为两组,每组各40例,两组均使用左氧氟沙星治疗,其中A组加用托特罗定和中成药(前列舒通)治疗,B组仅加用中成药(前列舒通)治疗。治疗6—8周后,通过NIH—CPSI评分评价两组治疗方法对患者的疗效。结果治疗后A组有效34例,有效率85%,B组有效24例,有效率60%,A组有效率高于B组(P〈0 .05)。结论对于Ⅲ型前列腺炎患者,托特罗定可明显改善患者排尿症状,且不良反应较低,患者耐受性较好。
Objective To evaluate the efficacy and safety of tolterodine for the treatment of men with chronic prostatitis (type Ⅲ). Methods Eighty nlen with chronic prostatitis(type Ⅲ)were randomly assigned to receive a Chinese medicine( n 40) or both tolterodine and a Chinese medicine(n 40) for 6 to 8 weeks. All the patients received oral levofloxacin simultaneously. Patient perception of treatment benefit,adverse reaction and NIH-CPSI were assessed. Results Patients receiving both toherodine and a Chinese medicine demonstrated sig- nificant improvement on NIH-CPSI than those receiving ouly a Chinese medicine. Conclusion Toherodine can improve the urinary, symptom effectively for men with prostatitis.
出处
《安徽医学》
2014年第4期491-493,共3页
Anhui Medical Journal